REN and type 2 diabetes mellitus: The main evidence that supports metformin as the first-line treatment in T2DM in terms of reducing cardiovascular events comes from the UKPDS, which was conducted over two decades ago, prior to the extensive application of cardioprotective drugs including renin–angiotensin system inhibitors and statins [11,29].